Effect of Curcuminoids on Pharmacokinetics and Pharmacodynamics of Atorvastatin in Hyperlipidemia Rats and Its Potential Mechanism
Biopharmaceutics & Drug Disposition · 2025-06 · 46 (3) · 112-126
DOI: 10.1002/bdd.70009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biopharmaceutics & Drug Disposition, online erschienen am 30.07.2025. Verfasst von Jiao Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China. Hauptthemen laut MEDLINE: Atorvastatin, Hyperlipidemias, Herb-Drug Interactions, Hydroxymethylglutaryl-CoA Reductase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 83 Literaturangaben. Gefördert von: the Chinese Medicine Administration of Heilongjiang Province, the National Science Foundation of Heilongjiang Province, the postgraduate funds for Heilongjiang University of Chinese Medicine.
Abstract (Originalsprache)
Curcuminoids (CURs), natural polyphenols, are often combined with atorvastatin to treat hyperlipidemia. In order to assess the safety of combination, the effect of CURs on Cytochrome P450 (CYP) 3A2 activity in rats was investigated. Additionally, the effect of CURs on pharmacokinetics and pharmacodynamics of atorvastatin in rats was evaluated. The effect of CURs on CYP3A2 activity was studied using the probe drug method (dapsone as a probe drug). Pharmacokinetic parameters of atorvastatin with or without CURs were calculated to evaluate herb‐drug interactions (HDIs). The effect of CURs on pharmacodynamics of atorvastatin was investigated by blood lipid, oxidative stress, aminotransferases, inflammatory factors and liver histopathology. C max , AUC, and t 1/2 of dapsone in CURs group significantly increased ( p < 0.05). C max , AUC, and t 1/2 of atorvastatin in combination group significantly increased both in normal and hyperlipidemia rats ( p < 0.01). Pharmacodynamics indexes of all treatment groups were significantly improved. There was no significant difference between AC group and combination group except HDL‐C, SOD and liver index. In conclusion, CURs combined with atorvastatin could not effectively enhance the lipid‐lowering effect or alleviate liver damage. However, CURs could inhibit CYP3A2 activity in rats and increase plasma exposure of atorvastatin, which might increase the risk of HDIs. The findings provided new insight into the combination of CURs and atorvastatin in treating hyperlipidemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin, China.
ORCID-Profile: Mingyu Cui
Förderung
- the Chinese Medicine Administration of Heilongjiang Province
- the National Science Foundation of Heilongjiang Province
- the postgraduate funds for Heilongjiang University of Chinese Medicine
Zitieren
APA
Li, J., Wang, J., Zhong, B., Wu, F., Yin, W., Wang, S., Yan, X., & Cui, M. (2025). Effect of Curcuminoids on Pharmacokinetics and Pharmacodynamics of Atorvastatin in Hyperlipidemia Rats and Its Potential Mechanism. Biopharmaceutics & Drug Disposition, 46(3), 112-126. https://doi.org/10.1002/bdd.70009
Vancouver
Li J, Wang J, Zhong B, Wu F, Yin W, Wang S, et al. Effect of Curcuminoids on Pharmacokinetics and Pharmacodynamics of Atorvastatin in Hyperlipidemia Rats and Its Potential Mechanism. Biopharmaceutics & Drug Disposition. 2025;46(3):112-126. doi:10.1002/bdd.70009
BibTeX
@article{Li2025,
author = {Li, Jiao and Wang, Jinzhen and Zhong, Benlu and Wu, Fan and Yin, Weihong and Wang, Siwen and Yan, Xueying and Cui, Mingyu},
title = {Effect of Curcuminoids on Pharmacokinetics and Pharmacodynamics of Atorvastatin in Hyperlipidemia Rats and Its Potential Mechanism},
journal = {Biopharmaceutics & Drug Disposition},
year = {2025},
volume = {46},
number = {3},
pages = {112--126},
doi = {10.1002/bdd.70009}
}
EUVIMED